GlassScriptPhysician profile
Leila N Creatore
NPI 1326686023
$4,025.19
in general payments reported to CMS, 2019-2025
30 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,700 · 2022: $1,183 · 2023: $613 · 2024: $58.38 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.22 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.04 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $750.95 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $227.22 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $216.21 | 2022-2024 | Tezspire, Breztri, Fasenra |
| Intercept Pharmaceuticals, INC. | $187.06 | 2021-2022 | |
| Pulmonx Corporation | $160.50 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Glaxosmithkline, LLC. | $151.28 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| United Therapeutics Corporation | $146.03 | 2023-2025 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $134.76 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $127.08 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $125.40 | 2023-2025 | Opsumit, Uptravi |
| Ardelyx, INC. | $93.37 | 2022 | |
| Redhill Biopharma INC. | $89.06 | 2021-2022 | |
| Harmony Biosciences LLC | $79.12 | 2023 | Wakix |
| Ironwood Pharmaceuticals, INC | $72.42 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $68.78 | 2021-2022 | |
| Mylan Specialty L.P. | $57.92 | 2023 | Yupelri |
| Daiichi Sankyo INC. | $57.62 | 2021 | |
| Janssen Biotech, INC. | $43.85 | 2021-2022 | |
| Celgene Corporation | $41.00 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.83 | 2022-2023 | Ofev |
| Amgen INC. | $29.32 | 2022 | |
| Philips North America LLC | $25.29 | 2024 | (Ak6) Vest Therapy |
| Genzyme Corporation | $20.44 | 2022 | |
| Axonics, INC. | $20.00 | 2021 | |
| Merck Sharp & Dohme LLC | $19.12 | 2022 | |
| Inogen, INC. | $16.50 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Vivus LLC | $15.10 | 2021 | |
| Electromed, INC. | $15.10 | 2023 | Smartvest |
| Medtronic, INC. | $12.82 | 2023 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leila Creatore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.